These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 38745582)

  • 21. Idarucizumab: A Review as a Reversal Agent for Dabigatran.
    Syed YY
    Am J Cardiovasc Drugs; 2016 Aug; 16(4):297-304. PubMed ID: 27388764
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting.
    Gendron N; Chocron R; Billoir P; Brunier J; Camoin-Jau L; Tuffigo M; Faille D; Teissandier D; Gay J; de Raucourt E; Suner L; Bonnet C; Martin AC; Lasne D; Ladhari C; Lebreton A; Bertoletti L; Ajzenberg N; Gaussem P; Morange PE; Le Cam Duchez V; Viallon A; Roy PM; Lillo-le Louët A; Smadja DM
    Front Med (Lausanne); 2020; 7():599626. PubMed ID: 33392223
    [No Abstract]   [Full Text] [Related]  

  • 23. Dabigatran Reversal With Idarucizumab in Patients With Renal Impairment.
    Eikelboom JW; van Ryn J; Reilly P; Hylek EM; Elsaesser A; Glund S; Pollack CV; Weitz JI
    J Am Coll Cardiol; 2019 Oct; 74(14):1760-1768. PubMed ID: 31582135
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Difficult reversal of dabigatran with idarucizumab in a multiple-trauma patient: A question of dose?
    Ströhle M; Rugg C; Schmid S; Fries D; Oswald E
    Trauma Case Rep; 2021 Apr; 32():100422. PubMed ID: 33665315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of Dabigatran Bleeding and Coagulopathy Using Idarucizumab in a Patient With Acute Kidney Injury.
    Vidal J; DePalma R; Forouzan L
    P T; 2018 Dec; 43(12):748-749. PubMed ID: 30559587
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Idarucizumab for the treatment of hemorrhage and dabigatran reversal in patients requiring urgent surgery or procedures.
    Vornicu O; Larock AS; Dincq AS; Douxfils J; Dogné JM; Mullier F; Lessire S
    Expert Opin Biol Ther; 2017 Oct; 17(10):1275-1296. PubMed ID: 28728489
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Idarucizumab for Reversal of Dabigatran-Associated Anticoagulation.
    Yogaratnam D; Ditch K; Medeiros K; Doyno C; Fong JJ
    Ann Pharmacother; 2016 Oct; 50(10):847-54. PubMed ID: 27389324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Idarucizumab for Dabigatran Reversal.
    Pollack CV; Reilly PA; Eikelboom J; Glund S; Verhamme P; Bernstein RA; Dubiel R; Huisman MV; Hylek EM; Kamphuisen PW; Kreuzer J; Levy JH; Sellke FW; Stangier J; Steiner T; Wang B; Kam CW; Weitz JI
    N Engl J Med; 2015 Aug; 373(6):511-20. PubMed ID: 26095746
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Experience with idarucizumab as a reverse agent of dabigatran].
    Bottaro FJ; Margan MM; Duboscq C; Ceresetto JM
    Medicina (B Aires); 2020; 80(4):405-410. PubMed ID: 32841148
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Two Dabigatran Fast Reversals in a 4-month Period - a Case Report.
    Fagundes V; Mesquita M
    Eur J Case Rep Intern Med; 2019; 6(12):001311. PubMed ID: 31893202
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Idarucizumab for Reversing Dabigatran-Induced Anticoagulation: A Systematic Review.
    Thibault N; Morrill AM; Willett KC
    Am J Ther; 2018; 25(3):e333-e338. PubMed ID: 27175894
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Idarucizumab for dabigatran reversal in daily clinical practice: A case series.
    Vene N; Mavri A; Božič-Mijovski M; Gregorič M; Uštar KK; Žerjav U; Gradišek P; Stecher A; Frol S; Nedog V; Detkova N; Kosi IE
    Eur J Anaesthesiol; 2020 Oct; 37(10):874-878. PubMed ID: 32175987
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rationale and design of a phase III safety trial of idarucizumab in children receiving dabigatran etexilate for venous thromboembolism.
    Albisetti M; Schlosser A; Brueckmann M; Gropper S; Glund S; Tartakovsky I; Brandão LR; Reilly PA
    Res Pract Thromb Haemost; 2018 Jan; 2(1):69-76. PubMed ID: 30046708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases.
    Vosko MR; Bocksrucker C; Drwiła R; Dulíček P; Hauer T; Mutzenbach J; Schlimp CJ; Špinler D; Wolf T; Zugwitz D
    J Thromb Thrombolysis; 2017 Apr; 43(3):306-317. PubMed ID: 28210988
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety, pharmacokinetics and pharmacodynamics of idarucizumab, a specific dabigatran reversal agent in healthy Japanese volunteers: a randomized study.
    Yasaka M; Ikushima I; Harada A; Imazu S; Taniguchi A; Norris S; Gansser D; Stangier J; Schmohl M; Reilly PA
    Res Pract Thromb Haemost; 2017 Oct; 1(2):202-215. PubMed ID: 30046691
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma.
    Edwards G; Roman C; Jithoo R; Mitra B
    Trauma Case Rep; 2018 Feb; 13():46-49. PubMed ID: 29644298
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes.
    van der Horst SFB; Martens ESL; den Exter PL; Bos MHA; van Mens TE; Huisman MV; Klok FA
    Thromb Res; 2023 Aug; 228():21-32. PubMed ID: 37267671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dabigatran reversal by idarucizumab in the setting of intracranial hemorrhage: A systematic review of the literature.
    Lu VM; Phan K; Rao PJ; Sharma SV; Kasper EM
    Clin Neurol Neurosurg; 2019 Jun; 181():76-81. PubMed ID: 31015061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Idarucizumab: What Should We Know?
    Cortese F; Calculli G; Gesualdo M; Cecere A; Zito A; De Vito F; Carbonara R; Carbonara S; Cortese AM; Ciccone MM
    Curr Drug Targets; 2018; 19(1):81-88. PubMed ID: 28950812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reversal of Dabigatran with Idarucizumab.
    Sodha NR; Sellke FW
    Expert Rev Cardiovasc Ther; 2016 Aug; 14(8):889-93. PubMed ID: 27362456
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.